ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among Chronic Obstructive Pulmonary Disease Patients (ECHO-COPD)

September 22, 2026 updated by: Rabia Hussain

Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Costs in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The Health Belief Model (HBM) will guide the content and delivery of the pharmacist-led educational intervention. The intervention will address six core HBM constructs: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy. The purpose of applying the HBM is to improve patients' understanding of chronic obstructive pulmonary disease (COPD) and promote positive behavioural changes, particularly improved medication adherence.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Al-Qassim Region
      • Buraidah, Al-Qassim Region, Saudi Arabia, 52391
        • Bander S Alshammeri
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participants must:

  1. Be adults aged 18-65 years.
  2. Be diagnosed with chronic obstructive pulmonary disease (COPD) stages I-III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
  3. Have visited or been admitted for a COPD exacerbation and are receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia.
  4. Be Arabic-speaking and capable of understanding study instructions.
  5. Be willing and able to provide written informed consent.

Exclusion Criteria:

Participants will be excluded if they:

  1. Are diagnosed with COPD stage IV.
  2. Have another significant pulmonary disease, including: Asthma, bronchiectasis, pneumonia, or cystic fibrosis.
  3. Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including: Hepatic dysfunction, renal dysfunction, psychiatric impairment or sensory impairment.
  4. Are immunocompromised or receiving immunosuppressive treatment.
  5. Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HBM-Based Educational Intervention

Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM.

The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department.

The programme will be delivered from study months 4 to 9.

Educational sessions will include:

  • Printed educational materials
  • Lectures
  • Individual counselling
  • Practical demonstrations
  • Personalised feedback
  • Problem-solving strategies
  • Motivational support
  • Interactive activities
  • Peer group discussions
  • Reinforcement of behavioural changes The six HBM constructs will guide the educational content.

Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM.

The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department.

The programme will be delivered from study months 4 to 9.

Educational sessions will include:

  • Printed educational materials
  • Lectures
  • Individual counselling
  • Practical demonstrations
  • Personalised feedback
  • Problem-solving strategies
  • Motivational support
  • Interactive activities
  • Peer group discussions
  • Reinforcement of behavioural changes The six HBM constructs will guide the educational content.
No Intervention: Standard Care

Participants in the control group will continue to receive routine/standard care provided by BCH.

They will not receive the additional structured pharmacist-led HBM-based educational intervention.

Both intervention and control participants will undergo the same baseline and post-intervention assessments.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication Adherence
Time Frame: Baseline and 6 months after initiation of the educational intervention.

Outcome Measure: Change in Medication Adherence Assessed by the Morisky Medication Adherence Scale-8.

Measurement Tool: Morisky Medication Adherence Scale-8 (MMAS-8), prevalidated Arabic version. The MMAS-8 is an 8-item self-reported measure of medication-taking behaviour, with a total score ranging from 0 to 8. Higher scores indicate better medication adherence, whereas lower scores indicate poorer adherence. Scores are commonly classified as low adherence (<6), medium adherence (6 to <8), and high adherence (8).

Baseline and 6 months after initiation of the educational intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life and Health Status
Time Frame: Baseline and 6 months after initiation of the educational intervention.

Outcome Measure: Change in Health Status Assessed by the COPD Assessment Test (CAT).

Description: The prevalidated Arabic COPD Assessment Test (CAT) will be used to assess health status in patients with chronic obstructive pulmonary disease. The CAT contains 8 items, each scored from 0 to 5, giving a total score range of 0-40. Higher scores indicate a greater impact of COPD on health status and therefore a worse outcome; lower scores indicate better health status.

Baseline and 6 months after initiation of the educational intervention.
Direct Healthcare Costs
Time Frame: Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.

Change in direct medical costs associated with COPD Direct healthcare cost data will be obtained from the clinical cost centre of Buraidah Central Hospital (BCH).

The costing analysis will include direct COPD-related healthcare resources such as:

  • Medications
  • Laboratory tests
  • Chest X-rays
  • Oxygen therapy Other direct medical resources documented within the approved data-collection instrument will be included as applicable.

Important Costing Specification The cost of delivering the educational intervention will not be included in the costing analysis.

The economic component of this study focuses on the direct cost of illness associated with COPD rather than the cost of implementing the educational intervention.

Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
HBM Constructs
Time Frame: Baseline and 6 months after initiation of the educational intervention.

Outcome Measure: Change in Health Beliefs Assessed by the Health Belief Model (HBM) Questionnaire.

Description: A prevalidated Arabic Health Belief Model (HBM) questionnaire will assess six constructs using a 3-point Likert scale (Disagree=0, Neutral=1, Agree=2). Perceived susceptibility: 3 items, range 0-6; severity: 5 items, 0-10; benefits: 3 items, 0-6; barriers: 5 items, 0-10; cues to action: 5 items, 0-10; self-efficacy: 5 items, 0-10. Higher scores indicate greater levels of the respective construct. For perceived barriers, higher scores indicate more barriers and therefore a less favourable outcome.

Baseline and 6 months after initiation of the educational intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

August 30, 2027

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

September 7, 2026

First Submitted That Met QC Criteria

September 7, 2026

First Posted (Actual)

September 11, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • USM-DSAP-2026-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.